Skip to main content
. Author manuscript; available in PMC: 2014 Apr 1.
Published in final edited form as: Eur J Clin Pharmacol. 2012 Sep 28;69(4):851–857. doi: 10.1007/s00228-012-1410-7

Figure 1.

Figure 1

Summary data for ALT and AST for study subjects for baseline and post-APAP dosing. Data are presented as median (line within box), 25th to 75th percentile (boundary of box), and 10 and 90th percentile (whiskers). No differences were present between ALT and AST at baseline compared to post-APAP dosing.